Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. by Duan, Tianjiao et al.
UCSF
UC San Francisco Previously Published Works
Title
Complement-dependent bystander injury to neurons in AQP4-IgG seropositive 
neuromyelitis optica.
Permalink
https://escholarship.org/uc/item/82s8h6bq
Journal
Journal of neuroinflammation, 15(1)
ISSN
1742-2094
Authors
Duan, Tianjiao
Smith, Alex J
Verkman, Alan S
Publication Date
2018-10-22
DOI
10.1186/s12974-018-1333-z
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH Open Access
Complement-dependent bystander injury
to neurons in AQP4-IgG seropositive
neuromyelitis optica
Tianjiao Duan1,2, Alex J. Smith1 and Alan S. Verkman1*
Abstract
Background: Aquaporin-4-immunoglobulin G (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder
(herein called NMO) is an autoimmune disease of the central nervous system in which AQP4-IgG binding to AQP4
on astrocytes results in complement-dependent astrocyte injury and secondary inflammation, demyelination, and
neuron loss. We previously reported evidence for a complement bystander mechanism for early oligodendrocyte
injury in NMO. Herein, we tested the hypothesis that complement bystander injury, which involves diffusion to
nearby cells of activated soluble complement components from complement-injured astrocytes, is a general
phenomenon that may contribute to neuronal injury in NMO.
Methods: Primary cocultures of rat astrocytes and cortical neurons were established to study complement-dependent
cell death after exposure to AQP4-IgG and complement. In animal experiments, AQP4-IgG was delivered to adult rats
by intracerebral injection. Cell cultures and rat brain were studied by immunofluorescence.
Results: In primary astrocyte-neuron cocultures, addition of AQP4-IgG and complement resulted in death of neurons
nearby astrocytes. Deposition of complement membrane attack complex C5b-9 was seen on neurons nearby astrocytes,
whereas C1q, the initiating protein in the complement pathway, was seen only on astrocytes. Neuron death was not
seen with a complement inhibitor, with C1q- or C6-depleted complement, in pure neuron cultures exposed to AQP4-IgG
and complement or in cocultures exposed to an astrocyte toxin. Intracerebral injection in rats of AQP4-IgG and a fixable
dead cell fluorescent marker produced death of neurons near astrocytes, with C5b-9 deposition. Neuron death was not
seen in rats receiving a complement inhibitor or in AQP4-IgG-injected AQP4 knockout rats.
Conclusion: These results support a novel mechanism for early neuron injury in NMO and provide evidence that
complement bystander injury may be a general phenomenon for brain cell injury following AQP4-IgG-targeted astrocyte
death.
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Background
Aquaporin-4-immunoglobulin G (AQP4-IgG) seropositive
neuromyelitis optica spectrum disorder (herein called
NMO) is an autoimmune demyelinating disease of the
central nervous system. NMO pathogenesis involves bind-
ing of AQP4-IgG autoantibodies to water channel AQP4
on astrocytes, resulting in complement- and cell-mediated
astrocyte injury, inflammation, demyelination, and neuron
loss [1–3]. Though demyelination and neuronal injury
could be secondary consequences of astrocyte death and
an inflammatory response, the rapid disease progression
seen in some NMO patients [4, 5] and the rapid patho-
logical changes seen in animal models during in vivo im-
aging of lesion formation [6, 7] suggest more direct
mechanisms by which astrocyte injury produces neuronal
injury and neurologic deficit. Several mechanisms have
been proposed to account for neuronal injury in NMO,
including excitotoxic damage following glutamate release
from injured astrocytes [8, 9] and secondary recruitment
of granulocytes and cytotoxic T cells [10, 11]. However,
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the role of excitotoxic mechanisms has been controversial
[12, 13], and although cellular mechanisms are probably
important, they are unlikely to cause the immediate dam-
age to surrounding cells following exposure to AQP4-IgG.
Complement activation is a major effector pathway in
NMO. NMO pathology in humans shows centrovascular
deposition of activated complement [14–16], and early
clinical trials data support the efficacy of a complement
inhibitor [17, 18]. Complement-dependent NMO path-
ology is also seen in experimental animal models of
NMO produced by passive transfer of AQP4-IgG [6, 7,
19]. We recently reported evidence for complement by-
stander injury to oligodendrocytes, in which comple-
ment activation following AQP4-IgG binding to AQP4
on astrocytes results in killing of nearby oligodendro-
cytes by a bystander mechanism involving local diffusion
of activated, soluble complement components, leading
to formation of the complement membrane attack com-
plex (MAC) on oligodendrocytes [20]. Complement by-
stander injury has been reported before in Rasmussen’s
encephalitis [21], cerebral artery smooth muscle cells
[22], and on cells surrounding amyloid plaques in post-
mortem samples from Alzheimer’s patients [23]. Low ex-
pression of CD59, a membrane-anchored complement
regulator protein that inhibits MAC formation on target
cells [24, 25], appears to be important for complement
bystander injury, probably because of the limited transfer
of soluble, metastable C5b67 from the primary target
cell to nearby bystander cells. Neurons have been re-
ported to express low levels of endogenous complement
inhibitors, including CD59 [26–28], and are therefore
potential targets for bystander damage.
Here, we tested the hypothesis that complement by-
stander injury is a general pathogenic mechanism in
NMO, accounting not only for early oligodendrocyte in-
jury and demyelination, but also for direct neuronal in-
jury. This study was motivated by in vivo pilot
experiments in rat brain in which neurons were identi-
fied as being frequently injured, along with oligodendro-
cytes, soon after intracerebral AQP4-IgG injection. Here,
experiments done in astrocyte-neuron cocultures and in
rat brain show that AQP4-IgG and complement do not
injure neurons directly, but kill neurons in close proxim-
ity to astrocytes by a complement bystander mechanism.
Methods
Materials
Recombinant purified AQP4-IgG (rAb-53) [29, 30] was
provided by Dr. Jeffrey Bennett (University of Colorado,
Aurora, CO). Fc hexamer Fc-μTP-L309C was as de-
scribed [31]. Chemicals were purchased from Sigma-Al-
drich (St. Louis, MO) unless specified otherwise.
Sprague-Dawley rats were purchased from Charles River
Laboratories (Wilmington, MA) and bred at UCSF.
AQP4−/− rats for control studies were generated by
CRISPR/Cas9 as reported [32]. All animal procedures
were approved by the University of California, San Fran-
cisco Animal Care and Use Committee (IACUC).
Cell culture
Primary cortical neuron cultures were generated from
the brains of embryonic day 18 (E18) Sprague-Dawley
rats (timed-pregnant, Charles River Laboratories, Wil-
mington, MA), as described [33, 34], with modification.
Briefly, the cerebral hemispheres were isolated and cor-
tical tissue was placed in cold Hank’s balanced salt solu-
tion (HBSS, pH 7.2; Invitrogen, Camarillo, CA) without
Ca2+ and Mg2+. After removal of the meninges, tissue
was diced, incubated for 10 min in 0.25% trypsin-EDTA
at 37 °C, and triturated with an 18-gauge needle. The
single-cell suspension was passed through a 70-μm
nylon strainer (Falcon, Corning, NY) and centrifuged.
The tissue pellet was resuspended in Neurobasal
medium containing 2% B27-supplement and 0.5 mM
Glutamax (Gibco, Grand Island, NY). Cells were plated
on PDL-coated 12-well plates at the density of 2 × 105/
ml. After 5–7 days in culture, neurons were used for
experiments.
Primary astrocyte cultures were generated from cere-
bral cortex of neonatal wild-type and AQP4−/− rats at
day 1 post-birth (P1), as described [35, 36]. Briefly, the
cerebral hemispheres were isolated and cortical tissue
was minced and incubated for 10 min at 37 °C in 0.25%
trypsin-EDTA. Dissociated cells were centrifuged at 500g
for 5 min and resuspended in Dulbecco’s modified Eagle
medium (DMEM) containing 10% FBS and 1% penicil-
lin/streptomycin in T75 flasks. After cell confluence (8–
10 days), flasks were shaken in a rotator at 180 rpm
overnight to purify astrocytes. The medium was replaced
with DMEM containing 3% FBS and 0.25 mM dibutyryl
cAMP to induce differentiation. Cultures were main-
tained for up to an additional 2 weeks. For cocultures,
astrocytes were plated on neurons and cocultured in
neuron medium overnight before experiments. The neu-
ron:astrocyte ratios of cocultures were from 5:1 to 20:1.
Complement-dependent cytotoxicity
Specified concentrations of AQP4-IgG (or control hu-
man IgG, Thermo Fisher Scientific, Rockford, IL) and
human complement (Innovative Research, Novi, MI)
were added in Hank’s buffer, and cells were incubated at
37 °C for specified times. In some experiments, cells
were exposed to serum of an AQP4-IgG seropositive
NMO patient who met the revised diagnostic criteria for
clinical disease. A fixable dead-cell stain (amine-reactive
dye, Invitrogen, Eugene, OR) at 1:1000 dilution was
added 30 min prior to cell fixation. In some experi-
ments, C1q- or C6-deficient human complement
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(Innovative Research, Novi, MI) was used instead of nor-
mal complement. In some experiments, the astrocyte
toxin α-aminoadipic acid (Santa Cruz Biotechnology,
Dallas, TX) at 2 mM was added to astrocyte-neuron co-
cultures for 75 min.
For live-cell real-time imaging, astrocyte-neuron co-
cultures were grown on 6-well plates and imaged by
phase-contrast optics using a 20×, 0.45 NA objective
lens on a Nikon Eclipse Ti microscope equipped with an
environmental chamber at 37 °C and 5% CO2. Ethidium
homodimer-1 (1 μM, Invitrogen, Eugene, OR) was added
to the culture medium prior to image acquisition. Trans-
mitted light (phase-contrast) and red fluorescence im-
ages were obtained sequentially every 2 min for a
30-min baseline period and then for 2 h following
addition of 20 μg/ml AQP4-IgG and 2% complement.
Rat studies
AQP4-IgG was delivered to adult wild-type or AQP4−/−
rats by intracerebral injection. Rats were anesthetized
with ketamine (100 mg/kg) and xylazine (10 mg/kg) and
mounted on a stereotaxic frame. Following a midline
scalp incision, a 1-mm-diameter burr hole was drilled
0.5 mm anterior and 3.5 mm lateral to the bregma for
insertion of a glass pipette with a 40-μm-diameter tip to
a depth of 3 mm. AQP4-IgG (or control IgG, each
15 μg) together with 6 μM fixable dead cell dye ethidium
homodimer-1 (EH-1) was infused in a volume of 3 μl
over 6 min by pressure injection. The glass pipette was
kept in place for 10 min before withdrawal to prevent
leaking. In some studies, the Fc hexamer Fc-μTP-L309C
(50 mg/kg, iv) or MK801 (10 mg/kg, ip) was adminis-
tered 2 h or 30 min, respectively, before intracerebral in-
jection of AQP4-IgG. At 90 min, rats were deeply
anesthetized and transcardiacally perfused with 200 ml
heparinized PBS and 200 ml of 4% paraformaldehyde
(PFA) in PBS. Brains were removed and post-fixed for
4 h in 4% PFA and cryoprotected in 20% sucrose for cut-
ting 7-μm-thick sections on a cryostat.
Immunofluorescence
Following treatments, cell cultures were rinsed in PBS,
fixed with 4% PFA for 15 min, and then blocked with 1%
BSA and 0.2% Triton-X100 in PBS for 1 h. Cultures were
incubated at room temperature for 2 h, and brain sec-
tions were incubated at 4 °C overnight with antibodies
against AQP4 (1:200, Santa Cruz Biotechnology), GFAP
(glial fibrillary acidic protein, 1:1000; Millipore), MAP2
(microtubule-associated protein 2, 1:100, Thermo Fisher
Scientific), NeuN (Neuronal Nuclei, 1:200; Millipore),
C1q (1:50, Abcam, Cambridge, MA), C5b-9 (1:100, Santa
Cruz Biotechnology), or CD59 (5 μg/ml, Lifespan Bio-
science), followed by the appropriate species-specific
Alexa Fluor-conjugated secondary antibody for 1 h
(5 μg/ml each, Invitrogen). In some control studies,
phosphatidylinositol-specific phospholipase C (PI-PLC)
(0.5 U/ml, Invitrogen) was added 1 h prior to experi-
ments to release the extracellular portion of glycopho-
sphoinositol (GPI)-anchored membrane protein CD59.
AQP4-IgG was detected using Alexa Fluor-conjugated
anti-human IgG. Sections were mounted with Vecta-
Shield (Vector Laboratories, Burlingame, CA), and im-
munofluorescence was visualized on a Nikon confocal
microscope using a 20×/0.5 N.A., 60×/1.25 N.A., or
100×/1.4 N.A. oil objective lens.
Results
Characterization of astrocyte-neuron cocultures
An astrocyte-neuron coculture model was established
with the goal of having relatively few, well-separated as-
trocytes with many surrounding neurons in order to fa-
cilitate imaging of bystander injury to neurons. Figure 1a
shows staining for GFAP (astrocyte marker) and MAP2
(neuron marker) in pure astrocyte and neuron cultures
and in cocultures generated using different cell ratios.
The astrocyte cultures were fully differentiated using
dibutyryl-cAMP for these studies, and astrocyte-neuron
cocultures were generated as described under the
“Methods” section. A neuron:astrocyte cell ratio of 20:1,
which showed relatively few and well-separated astro-
cytes, was used for subsequent experiments.
Figure 1b (top panels) shows that the individual astro-
cyte and neuron cultures were > 95% pure as seen by
GFAP and MAP2 immunofluorescence with DAPI cost-
aining. AQP4 and CD59 immunofluorescence showed,
as expected, AQP4 expression only on astrocytes, with
AQP4-deficient astrocytes generated from AQP4−/− rats
as control (Fig. 1b, lower panels). CD59 was expressed
on astrocytes, with little expression seen on neurons.
The control for CD59 immunofluorescence was treat-
ment with the enzyme PI-PLC, which cleaves the extra-
cellular CD59 antigen from its membrane-spanning
domain. In astrocyte-neuron cocultures, CD59 expres-
sion was seen on astrocytes and not on neurons (Fig. 1c).
At 1 h following incubation with AQP4-IgG, AQP4-IgG
was seen on astrocytes but not neurons as detected
using a fluorescent anti-human IgG secondary antibody
(Fig. 1d). Therefore, astrocytes but not neurons are the
target of the pathogenic NMO anti-AQP4 autoantibody.
Complement bystander killing of neurons in astrocyte-
neuron cocultures
Complement-dependent cytotoxicity was produced by
incubation of astrocyte-neuron cocultures with AQP4-
IgG and human complement. A fixable dead cell stain
was included in order to visualize dead cells. In pure
astrocyte and neuron cultures, > 60% of astrocytes were
stained with dead cell dye following 2 h exposure to
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AQP4-IgG and complement, whereas < 5% of neurons
were stained (Fig. 2a). In the astrocyte-neuron cocul-
tures, dead cell-stained astrocytes were seen (Fig. 2b, yel-
low filled arrowheads), as well as dead cell-stained
neurons (yellow open arrowheads), generally in close
proximity to astrocytes. Dead cell-stained neurons were
seen near both dead cell-stained and non-stained astro-
cytes. Figure 2b (right) summarizes the percentage of
dead neurons at different distances from the center of
dead astrocytes, showing preferential killing of neurons
within 200 μm of dead astrocytes. A similar pattern of
dead neurons nearby astrocytes was seen using NMO
patient serum instead of the recombinant AQP4-IgG
antibody (Fig. 2c).
Time-lapse imaging was done to visualize in real time
the injury to astrocytes and neurons following exposure
to AQP4-IgG and complement. Phase-contrast and
fluorescence imaging was done to visualize all cells and
AQP4CD59
AQP4
CD59 CD59
CD59 CD59
AQP4
AQP4
AQP4
AQP4
pure AQP4+/+ astrocytes pure AQP4-/- astrocytes pure neurons
GFAP
DAPI
b
MAP2
DAPI
CD59
GFAP / MAP2
pure neurons pure astrocytes5:1 10:1 20:1
neuron : astrocyte ratio
a
100 m
100 m
100 m
GFAP
DAPI
CD59
CD59
GFAP
MAP2
merge
merge
astrocyte-neuron coculturesc
MAP2
MAP2
GFAPAQP4
AQP4 hIgG
50 m
d astrocyte-neuron cocultures
Fig. 1 Characterization of rat astrocyte-neuron cocultures. a GFAP and MAP2 immunofluorescence of pure neuron cultures, pure astrocyte
cultures, and astrocyte-neuron cocultures at indicated cell ratios. b (top panels) GFAP or MAP2 immunofluorescence (with DAPI counterstaining)
of pure AQP4+/+ and AQP4−/− astrocyte cultures and pure neuron cultures. (lower panels) CD59 and AQP4 immunofluorescence. Where indicated
(bottom row), cells were incubated with PI-PLC 1 h prior to fixation. c CD59 immunofluorescence of astrocyte-neuron cocultures costained with
GFAP or MAP2. d (upper) AQP4 immunofluorescence of astrocyte-neuron cocultures costained with GFAP and MAP2. (lower) AQP4-IgG (human
IgG, hIgG) immunofluorescence (visualized with secondary anti-human IgG antibody) in astrocyte-neuron cocultures following 1 h incubation
with 20 μg/ml AQP4-IgG, costained with AQP4 and MAP2. Micrographs representative of studies done of three sets of cultures
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their injury. Neurons and astrocytes were readily differ-
entiated based on morphological criteria and the weak
phase-halo of the very flat astrocytes (Fig. 2d, left panel).
Upon addition of AQP4-IgG and complement, astro-
cytes responded with morphological rearrangements;
however, only a subset of cells was damaged severely
enough for full membrane permeabilization to occur
(not shown). Neurons adjacent to astrocytes showed
neurite blebbing and membrane lysis with uptake of
ethidium homodimer (Fig. 2d, right panel and
Additional file 1: Movie 1).
C5b-9 and C1q immunostaining was done to investi-
gate whether neuronal injury was caused by a comple-
ment bystander mechanism, which would predict C5b-9
on both astrocytes and nearby injured neurons, whereas
C1q, the initiating complement protein, only on astro-
cytes. C5b-9 immunofluorescence was seen on many
dead cell-stained astrocytes and neurons in the cocul-
tures (Fig. 3a). Figure 3b indicates C5b-9 deposition on
astrocytes as well as on neurons near astrocytes, whereas
C1q immunofluorescence was seen only on astrocytes.
Figure 3c summarizes the percentage of C5b-9 and C1q
positive neurons at different distances from C5b-9 and
C1q positive astrocytes. These results support a comple-
ment bystander mechanism in which C1q binding to
AQP4-IgG on astrocytes results in deposition of the
cytotoxic C5b-9 complex on both astrocytes and nearby
neurons.
pure neuron culture pure astrocyte culture
AQP4-IgG control IgG
a
b
c before 0.5 h AQP4-IgG/hC 2 h AQP4-IgG/hC
50 m
dead cell
GFAP
dead cell
MAP2
dead cell
GFAP
MAP2
100 m
50 m
AQP4-IgG
distance from astrocyte center ( m)
control IgG
<200 200-300 >300
40
30
20
10
0
50
*
50 m50 m
dead cell
GFAP
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d
Fig. 2 Complement-mediated neuron injury in astrocyte-neuron cocultures. a Complement-dependent cytotoxicity in pure neuron and pure astrocyte
cultures following incubation with 20 μg/ml AQP4-IgG and 2% human complement for 2 h, with fixable dead cell marker (reactive amine dye, labeled
“dead cell”). Cultures were immunostained for GFAP and MAP2, with dead cells stained red. b Cocultures were incubated as in a and immunostained
for GFAP (green) and MAP2 (gray), with dead cells red. Expanded images (lower panels) showing dead astrocytes (filled yellow arrowheads) and
nearby dead neurons (open yellow arrowheads) in representative fields. Bar graph at the right shows percentage of dead neurons at different
distances from the center of dead astrocytes (mean ± S.E.M., n = 6 cultures, total 32 astrocytes imaged, *P < 0.01 comparing AQP4-IgG vs. control IgG).
c Cocultures were incubated with 1% NMO patient serum and 5% human complement and immunostained as in panel b. d Panels from time-lapse
image sequence (see Additional file 1: Movie 1) showing astrocytes and neurons in coculture before and at 0.5 and 2 h after addition of 20 μg/ml
AQP4-IgG and 2% human complement containing dead cell marker ethidium homodimer-1. Labels in the left panel: n, neuron; a, astrocyte. Filled
arrowheads point to early damage of neurons in contact with astrocytes, and red color is due to uptake of dead cell marker. Open arrowheads
indicate sites of neurite blebbing and degeneration
Duan et al. Journal of Neuroinflammation          (2018) 15:294 Page 5 of 11
Control studies were done to support a complement
bystander mechanism for neuron killing in the
astrocyte-neuron cocultures. Cocultures incubated with
AQP4-IgG and C1q-depleted serum did not show cell
killing or C5b-9 deposition, indicating that activation of
classic complement pathway is the effector of bystander
injury (Fig. 4a (i)). Incubation of cocultures with
AQP4-IgG and C6-depleted serum did not produce
cytotoxicity, indicating that neuron killing is the conse-
quence of MAC (C5b-9) deposition rather than up-
stream anaphylotoxins or other mediators (Fig. 4a (ii)).
Cytotoxicity was not seen in the presence of a comple-
ment inhibitor (Fig. 4a (iii)) or in AQP4-deficient cocul-
tures in which astrocytes were cultured from AQP4−/−
rats (Fig. 4a (iv)). In a separate control, cocultures were
incubated with the astrocyte-selective toxin
α-aminoadipic acid [37, 38] in which the incubation time
and toxin concentration were chosen in initial studies to
cause killing of many astrocytes but few neurons (in
pure cultures). Exposure of pure cultures to 2 mM
α-aminoadipic acid for 75 min resulted in ~ 85% astro-
cyte death and ~ 10% neuron death. Incubation of
cocultures with α-aminoadipic acid under these condi-
tions resulted in killing of astrocytes but not neurons
(Fig. 4b), suggesting that mediators or other factors re-
leased from dying astrocytes are not responsible for
neuronal injury.
Complement bystander injury to neurons in a rat model
of NMO
To investigate complement bystander injury in vivo, rats
were administered AQP4-IgG by intracerebral injection,
together with the dead cell dye ethidium homodimer-1
(EH-1) (Fig. 5a). Rats were sacrificed at 90 min, and
brains were perfusion-fixed for frozen sections. Figure 5b
shows many dead cells near the needle tract in rats re-
ceiving AQP4-IgG. In control studies, few or no dead
cells were seen with injection of non-NMO human IgG
instead of AQP4-IgG, when rats were pre-treated with
the Fc hexamer complement inhibitor or when
AQP4-IgG was injected in AQP4−/− rats. NeuN im-
munofluorescence of neurons with GFAP immunofluor-
escence of astrocytes showed many red-stained dead
astrocytes, as well as nearby dead neurons and some
AQP4-IgG
control-IgG
C5b-9 C5b-9
AQP4-IgG
control-IgG
AQP4-IgG
control-IgG
GFAP MAP2 merge
GFAP MAP2 merge
a
b c
50 m
dead cell
C5b-9
GFAP
dead cell
C5b-9
MAP2
C5b-9
C1q
50 m
50 m
z
C1q
40
0
*
distance from
C5b-9
<200 200-300
10
30
20
astrocyte center ( m)
>300
Fig. 3 Evidence for a complement bystander mechanism for AQP4-IgG/complement-induced neuron injury in astrocyte-neuron cocultures. a
C5b-9 immunofluorescence (green) in astrocyte-neuron cocultures with dead cell stain (red) at 2 h after incubation with 20 μg/ml AQP4-IgG and
2% human complement, immunostained for GFAP or MAP2 (gray). b C5b-9 and C1q immunofluorescence of cocultures with cell markers GFAP
and MAP2 treated as in a. Filled arrowheads indicate C5b-9 or C1q on astrocytes, and open arrowheads show C5b-9 on neurons. c Percentage of
C5b-9 and C1q positive neurons at different distances from C5b-9 or C1q positive astrocytes (mean ± S.E.M., n = 6, *P < 0.01 comparing AQP4-IgG
vs. control IgG)
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other cell types not stained with NeuN or GFAP (Fig. 5c).
In the area within and just around the needle tract, ~
80% of astrocytes were dead (red-stained), with ~ 55% of
dead neurons nearby (within 200 μm) astrocytes (sec-
tions from 3 rats examined).
To investigate if excitotoxic mechanisms might con-
tribute to the early neuron injury observed in response
to AQP4-IgG, the NMDA receptor antagonist MK801
(10 mg/kg, ip) [39, 40] was injected 30 min before intra-
cerebral injection of AQP4-IgG and EH-1. Figure 5d
shows similar EH-1 staining by neurons in the presence
and absence of MK801, suggesting minimal contribution
of excitotoxicity to neuron cell death in this model.
C5b-9 and C1q immunofluorescence in rats injected
with AQP4-IgG and EH-1 showed C5b-9 on dead astro-
cytes as well as on nearby dead neurons (Fig. 6a). In rats
injected with AQP4-IgG (without EH-1), immunofluor-
escence of C1q, GFAP, and NeuN showed C1q depos-
ition only on astrocytes (Fig. 6b, top panels), whereas
C5b-9 was seen on both astrocytes and nearby neurons
(Fig. 6b, bottom panels). Figure 6c shows CD59 colocali-
zation with GFAP in astrocytes, but not with NeuN on
neurons in (non-injected) rat brain, which is consistent
with the cell culture studies showing CD59 on astrocytes
but not neurons.
Discussion
This study reports evidence for complement bystander
killing of neurons in astrocyte-neuron cocultures in vitro
and in rats in vivo. Astrocyte-neuron cocultures exposed
to AQP4-IgG or NMO patient serum and complement
showed injury and death in neurons very near astrocytes.
Time-lapse imaging revealed early injury to neurons
near astrocytes even before gross plasma membrane
permeabilization and uptake of the dead cell stain.
Neuron death was not seen in the absence of AQP4-IgG
or with complement inhibition, with C1q- or
C6-depleted serum, or with an astrocyte toxin, implicat-
ing a complement-dependent mechanism initiated by
AQP4-IgG binding to astrocytes. The deposition of
C5b-9 on astrocytes and injured nearby neurons, with
C1q deposition only on astrocytes, indicates that activa-
tion of the classical complement cascade on astrocytes
leads to MAC deposition on both astrocytes and nearby
C6-depleted serum
dead cell
AQP4
MAP2
+ Fc hexamer AQP4-/- astrocytea
control -aminoadipic acidb
C5b-9
GFAP
MAP2
dead cell
AQP4
MAP2
50 m
C1q-depleted serum
ii iii ivi
100 m
Fig. 4 Control studies supporting a complement bystander mechanism for neuron injury. a Astrocyte-neuron cocultures were incubated for 2 h
with 20 μg/ml AQP4-IgG and 2% C1q-depleted serum (i) or with 20 μg/ml AQP4-IgG and 2% C6-depleted serum (ii); cocultures were incubated
for 2 h with 20 μg/ml AQP4-IgG and 2% human complement that was pre-exposed for 1 h to 1 μg/ml Fc hexamer (complement inhibitor) (iii);
AQP4−/− astrocyte-neuron cocultures were incubated for 2 h with 20 μg/ml AQP4-IgG and 2% human complement (iv). GFAP, MAP2, and C5b-9
immunofluorescence as indicated, with dead cells stained red. b Direct astrocyte injury caused by α-aminoadipic acid. Cocultures were exposed
to 2 mM α-aminoadipic acid for 75 min, with AQP4 and MAP2 immunofluorescence and dead cell stain shown. Filled arrowheads show dead
astrocytes. Micrographs representative of three sets of studies done on different cocultures
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neurons. Astrocyte killing by a selective toxin in the co-
cultures did not result in neuron killing, indicating the
factors released from dead astrocytes are not responsible
for neuron killing in the coculture experiments. In rats
in vivo, dead neurons near dead astrocytes were seen at
90 min after intracerebral administration of AQP4-IgG,
with C5b-9 deposition on astrocytes and neurons, but
C1q deposition only on astrocytes. Neuron cytotoxicity
was not seen with complement inhibition, with
non-NMO human IgG, or in AQP4−/− rats. Though it is
not possible to exclude mechanisms other than comple-
ment bystander injury to explain the early neuron death
control IgG AQP4-IgG
b
EH-1 NeuN GFAPc
EH-1 NeuN GFAP
50 m
Fc heximer, iv sacrificecontrol or AQP4-IgG + EH-1
Intracerebral Injection
-2 h 0 90 mina
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AQP4-IgG + EH-1
Intracerebral Injection
100 m
10 m
d EH-1 NeuN GFAP
AQP4-IgG control IgG AQP4-IgG
100 m 50 m
Fig. 5 Complement bystander killing of neurons near astrocytes in rat brain following intracerebral AQP4-IgG injection. a AQP4-IgG (15 μg) (or 15 μg
control IgG) and dead cell stain EH-1 (6 μM) in a 3-μl volume was injected in cortex and striatum of rat brain, and rats were sacrificed at 90 min. In some
studies, rats were injected with Fc hexamer (50 mg/kg, iv) by tail vein 2 h before or MK801 (10 mg/kg, ip) 30 min before intracerebral injection of AQP4-
IgG. b Low-magnification micrographs showing dead cells (red EH-1 fluorescence), NeuN (green), and GFAP (blue) for studies done in AQP4+/+ rats, Fc
hexamer-treated AQP4+/+ rats, and AQP4−/− rats. c High-magnification confocal images of AQP4+/+ rat brain at 90 min after injection of AQP4-IgG (or
control IgG) and EH-1 showing dead astrocytes and nearby dead injured neurons. Expanded images on the right showing representative fields. Filled
arrowheads show dead astrocytes, open arrowheads show nearby dead neurons, and arrow points to a non-neuron, non-astrocyte dead cell. d Rats were
injected with MK801 (10 mg/kg, ip) 30 min before intracerebral injection of AQP4-IgG (or control IgG) and EH-1. Imaging showing dead cells (red EH-1
fluorescence), NeuN (green), and GFAP (blue). Filled arrowheads show dead astrocytes, open arrowheads show nearby dead neurons, and arrow points to
a non-neuron, non-astrocyte dead cell. Representative of micrographs done on sections from three rats
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following AQP4-IgG in vivo, similar levels of neuronal
damage were observed in control rats and rats treated
with the NMDA receptor antagonist MK801, suggesting
that excitotoxic mechanisms do not substantially con-
tribute to the observed cell death.
The generality of complement bystander injury in NMO
adds to the list of proposed mechanisms linking the
AQP4-IgG astrocytopathy to downstream neurological
deficit and has potential implications for treatment of
NMO. Complement bystander injury to neurons could ac-
count for the early and marked neurological deficit seen
in some NMO patients, as well as for the rapid early
neuron loss in experimental animal models of NMO. In
addition to neuronal injury from a complement bystander
mechanism, as reported here, and oligodendrocyte injury
as we reported before [20], we speculate that other cell
types in the central nervous system may be injured simi-
larly, such as microvascular endothelial cells and pericytes
lining the blood-brain barrier in close contact with
AQP4-enriched astrocyte foot processes. With regard to
NMO therapeutics, early loss of neuron and axons would
limit the potential efficacy of remyelination therapeutics
[41, 42]. Complement bystander injury would be pre-
vented by inhibition of the classical complement pathway
C5b-9
merge
merge
NeuN
NeuN
GFAP
GFAP
C1q
b
GFAP C5b-9EH-1 merge
EH-1 NeuN C5b-9 merge
a
c
astrocytes
neurons
GFAP
NeuN
merge
merge
CD59
CD59
10 m
20 m
10 m
Fig. 6 Evidence for complement bystander killing of neurons in rat brain. a Brains were injected with AQP4-IgG and EH-1 and harvested at 90 min as
in Fig. 5. High-magnification confocal micrographs showing colocalization of EH-1, GFAP, and C5b-9 (top, filled arrowheads) and EH-1, NeuN, and C5b-
9 (bottom, open arrowheads). b Brains were injected with AQP4-IgG alone (without EH-1) and harvested at 90 min. C1q colocalization with GFAP and
NeuN, and C5b-9 colocalization with GFAP and NeuN (bottom). Filled arrowheads show C5b-9 or C1q deposition on astrocytes, and open arrowheads
show C5b-9 on neurons. c CD59 immunofluorescence with GFAP or NeuN in control (non-injected) rat. Filled arrowheads indicate CD59 on astrocytes.
Representative of micrographs done on sections from three rats
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or earlier steps in NMO pathogenesis such as AQP4-IgG
binding to AQP4 or by drugs or maneuvers to increase
CD59 expression in the secondarily injured cells. Comple-
ment bystander injury would be relatively insensitive to
drugs acting on more downstream disease pathogenesis
mechanisms such as general immunosuppressants.
Though the data here provide strong evidence for
complement bystander killing of neurons, several limita-
tions are noted. As human specimens were not studied,
the significance of complement bystander injury to neu-
rons in human NMO is uncertain. Even if specimens
from humans with active NMO disease were available, it
would likely be difficult to identify dead neurons because
of their clearance, and the lack of a dead cell stain and
defined AQP4-IgG exposure time as in the rat studies
here. Though the in vitro cocultures allowed clear-cut
interpretation of the immunofluorescence data because
of the well-demarcated cell distribution in two dimen-
sions and the specification of precise solution compos-
ition, the culture system does not recapitulate many
aspects of the central nervous system, such as the
blood-brain barrier, the complex three-dimensional net-
work of many different brain cell types, and inflamma-
tory effectors. It is therefore not possible in the in vivo
rat studies to exclude contributions from additional
mechanisms of early neuronal injury following astrocyte
death, such as excitotoxic injury or injury caused by in-
flammatory mechanisms such as cytokine release by as-
trocytes or microglial activation.
Conclusions
In conclusion, the evidence here for a complement by-
stander mechanism for neuronal injury in NMO sup-
ports the generality of complement bystander injury to
brain cell types implicated in NMO pathology, including
neurons, oligodendrocytes, and perhaps microvascular
endothelia and other cell types. Bystander injury may
also be relevant to cellular injury mechanisms such as
leukocyte degranulation following AQP4-IgG-induced
antibody-dependent cellular cytotoxicity.
Additional file
Additional file 1: Movie 1. Time-lapse imaging of astrocyte-neuron
coculture following addition of AQP4-IgG and complement as in Fig. 2.
Cultures were imaged for 30 min before and 2 h following addition of
AQP4-IgG and complement. (AVI 4660 kb)
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